Astragaloside IV

Astragaloside IV is an inhibitor of ERK and NF-kB and related targets used in studies of PI3K-Akt-mTOR Signaling and MAPK / ERK Signaling and related signaling programs. In practice, this places the compound in experiments that measure growth-factor signaling, survival control, and nutrient-sensing outputs and mitogenic kinase cascades, proliferation control, and differentiation-linked signaling in autophagy, cancer, and cardiovascular models.

By inhibiting ERK and NF-kB and related targets, Astragaloside IV can be used to examine growth-factor signaling, survival control, and nutrient-sensing outputs and mitogenic kinase cascades, proliferation control, and differentiation-linked signaling. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In autophagy, cancer, and cardiovascular models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving ERK and NF-kB and related targets
• Pathway perturbation studies connected to PI3K-Akt-mTOR Signaling and MAPK / ERK Signaling and related signaling programs
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, Astragaloside IV is appropriate when a defined chemical perturbant is needed to connect ERK and NF-kB and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in autophagy, cancer, and cardiovascular models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.